1. bookAHEAD OF PRINT
Dettagli della rivista
License
Formato
Rivista
eISSN
2501-062X
Prima pubblicazione
30 Mar 2015
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
Accesso libero

Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia

Pubblicato online: 01 Nov 2022
Volume & Edizione: AHEAD OF PRINT
Pagine: -
Ricevuto: 01 Oct 2022
Dettagli della rivista
License
Formato
Rivista
eISSN
2501-062X
Prima pubblicazione
30 Mar 2015
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, dkk. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca Cancer J Clin, 2021;71:209–249.10.3322/caac.2166033538338 Search in Google Scholar

2. Groot PMD, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Translational lung cancer research, 2018;7(3): 220-233.10.21037/tlcr.2018.05.06603796330050761 Search in Google Scholar

3. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer, Version 4.2021-March 3, 2021. Search in Google Scholar

4. Ayoola A, Barochia A, Belani K, Belani CP. Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update. Cancer Investigation, 2012;30:433-446.10.3109/07357907.2012.66669122571344 Search in Google Scholar

5. Schwartz LH, Litiere S, Vries ED, Ford R, Gwyther S, Mandrekar S, dkk. RECIST 1.1 – Update and Clarification: From the RECIST Committee. Eur J Cancer, 2016; 62: 132–137.10.1016/j.ejca.2016.03.081573782827189322 Search in Google Scholar

6. Yoshida T, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, dkk. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboringan EGFR mutation. Lung Cancer, 2015.10.1016/j.lungcan.2015.09.02526604031 Search in Google Scholar

7. Barron F, Cardona AF, Corrales L, Ramirez-Tirado LA, Caballe-Perez E, Sanchez G, dkk. Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation. J Thorac Dis, 2018;10(4):2166-2178.10.21037/jtd.2018.03.106594949029850120 Search in Google Scholar

8. Gomez XE, Soto A, Gomez MA. Survival and prognostic factors in non-small cell lung cancer patients with mutation of the EGFR gene treated with tyrosine kinase inhibitors in a peruvian hospital. Am J Cancer Res, 2019;9(5):1009-1016. Search in Google Scholar

9. Kim SY, Myung JK, Kim HR, NA II, Koh JS, Baek HJ, dkk. Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma. Tuberc Respir Dis, 2019;82:62-70.10.4046/trd.2018.0004630433129926551 Search in Google Scholar

10. Igawa S, Sasaki J, Otani S, Ishihara M, Takakura A, Katagiri M, dkk. Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations. Oncology, 2015;89:275–280.10.1159/00043870326335629 Search in Google Scholar

11. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, dkk. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. British Journal of Cancer, 2014;110:55-62.10.1038/bjc.2013.721388730924263064 Search in Google Scholar

12. Rotella V, Fornaro L, Vasile E, Tibaldi C, Boldrini L, Chella A, dkk. EGFR and KRas mutations in women with lung adenocarcinoma: implications for treatment strategy definition. Journal of Experimental and Clinical Cancer Research, 2014;33:7710.1186/s13046-014-0077-6419872625300933 Search in Google Scholar

13. Yu JY, Yu SF, Wang SH, Bai H, Zhao J, An TT, dkk. Clinical outcomes of EGFRTKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 2. Chinese Journal of Cancer, 2016;35:30.10.1186/s40880-016-0086-2480287527001083 Search in Google Scholar

14. Ouyang W, Yu J, Huang Z, Chen G, Liu Y, Liao Z, dkk. Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. Journal of Cancer, 2020; 11(8):2060-2067.10.7150/jca.37991705292432127933 Search in Google Scholar

15. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 2008;26(14):2350-2357.10.1200/JCO.2007.15.228018467727 Search in Google Scholar

16. Rozensztajn N, Ruppert AM, Lavole A, Leprieur EG, Duruisseaux M, Vieira T, dkk. Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors. Cancer Medicine, 2014;3(1):61-69.10.1002/cam4.180393039024408092 Search in Google Scholar

17. Tsai MJ, Hung JY, Lee MH, Kuo CY, Tsai YC, Tsai YM, dkk. Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors. Cancer, 2018; 10.10.3390/cancers10110434626644630428509 Search in Google Scholar

18. Zhang P, Nie X, Bie Z, Li L. Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma. Medicine, 2018;97:910.1097/MD.0000000000010006585173829489642 Search in Google Scholar

19. Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa SI, Saka H, dkk. he Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR)Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials. The Oncologist, 2015;20:307–315.10.1634/theoncologist.2014-0285435079725657199 Search in Google Scholar

20. Taniguchi Y, Tamiya A, Nakahama K, Naoki Y, Kanazu M, Omachi N, dkk. Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors. Oncology Letters, 2017;14:7589-7596.10.3892/ol.2017.7125575525829344206 Search in Google Scholar

21. Hsu F, Caluwe AD, Anderson D, Nichol A, Toriumi T, Ho C. Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations. Curr Oncol, 2017 Aug;24(4):228-233.10.3747/co.24.3496557645828874890 Search in Google Scholar

22. Xu C, Yao X, Li T, Wang J, An B, Wang J, dkk. Pretreatment neutrophil-tolymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer. Transl Cancer Res, 2020;9(4):2875-2883.10.21037/tcr.2020.02.28879761135117644 Search in Google Scholar

23. Tang M, Gao X, Sun H, Tian S, Dong J, Liu Z, dkk. Neutrophil-Lymphocyte Ratio as a Prognostic Parameter in NSCLC Patients Receiving EGFR-TKIs: A Systematic Review and Meta-Analysis. Journal of Oncology, 2021.10.1155/2021/6688346784025733542732 Search in Google Scholar

24. Phan TT, Ho TT, Nguyen HT, Nguyen HT, Tran TB, Nguyen ST. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI. International Journal of General Medicine, 2018;11:423–430.10.2147/IJGM.S174605625010630510441 Search in Google Scholar

25. Uribe-Querol E, Rosales C. Neutrophils in Cancer: Two Sides of the Same Coin. Journal of Immunology Research, 2015;2015.10.1155/2015/983698470693726819959 Search in Google Scholar

26. Won YW, Han JY, Lee GK, Park SY, Lim KY, Yoon KA, dkk. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. J Clin Pathol, 2011;64:947e952.10.1136/jclinpath-2011-20016921725039 Search in Google Scholar

27. Jiang H, Zhu M, Li Y, Li Q. Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer. Mol Clin Oncol, 2019; 11(3): 301–30810.3892/mco.2019.1881663621031384460 Search in Google Scholar

28. Matsuo N, Azuma K, Sakai K, Hattori S, Kawahara A, Ishii H, dkk. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. Scientific Report, 2016;6.10.1038/srep36458509555127811988 Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo